Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03794817 · ClinicalTrials.gov registry record

Immune Monitoring in Sensitized Patients at Risk of Rejection

A clinical trial, sponsored by University of California, San Francisco.

Completed
Registry status
112
Enrollment target

NCT03794817: Completed study, sponsored by University of California, San Francisco.

NCT03794817 is a clinical trial that has completed, run by University of California, San Francisco. The registered enrollment target is 112 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03794817 has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
112 participants
Enrollment target

Study Summary

The purpose of this study is to test the effect of anti-rejection medications on your immune system

Primary Outcome

Pretransplant Kidney Solid Organ Response Test (kSORT) predictive value of rejection in the first 6 months after transplantation

Trial Details

FieldValue
Enrollment Target 112 participants
Start Date 2015-08-20
Est. Completion 2017-09-08

What the finished NCT03794817 record still lists

NCT03794817 is an observational study that tracks outcomes without assigning an intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT03794817 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03794817 about?

NCT03794817 is a clinical study titled "Immune Monitoring in Sensitized Patients at Risk of Rejection". The purpose of this study is to test the effect of anti-rejection medications on your immune system

What is the current status of trial NCT03794817?

This trial is currently completed. The enrollment target is 112 participants. The study started on 2015-08-20. Estimated completion is 2017-09-08.

Who is sponsoring clinical trial NCT03794817?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04511013 · 112 participants · Phase 2

    A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

  • NCT04551560 · 112 participants · NA

    Stress and Congestive Heart Failure

  • NCT04872166 · 112 participants · Phase 1

    A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

  • NCT05024773 · 112 participants · Phase 3

    Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03794817, the US trial registry maintained by the National Library of Medicine. NCT03794817 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.